Document is current
Any future updates will be listed below
-
Authors
Wang, Chunxue
Mariani, Sara
Damiano, Robert J.
Lajevardi-Khosh, Arad
Silva, Ikaro
Ruebush, Laura E.
McFarlane, Daniel
Deutz, Nicolaas E. P.
Conroy, Bryan
-
Funding
Funding for this research was provided by:
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
Defense Threat Reduction Agency (HDTRA121C0006)
- License Information
-
More Information
Article History
Received: 1 November 2024
Accepted: 17 March 2025
First Online: 26 March 2025
Declarations
: The field study reported here was performed in accordance with relevant guidelines and regulations, including receiving preapprovals for all protocols by the Texas A&M University Institutional Review Board review boards and Human Research Protection Official, informed consent from the participants and the trial registration on clinicaltrials.gov (NCT05346302).
: Authors CW, SM, RD, AL, IS and BC are employees of Philips North America. Author DM was an employee of Philips North America. Authors LR, GC and ND are employees of Texas A&M University. All authors declare no other competing interests.
